Spots Global Cancer Trial Database for metastatic malignant neoplasm to brain
Every month we try and update this database with for metastatic malignant neoplasm to brain cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | NCT01332929 | Metastatic Mali... | Bevacizumab | 18 Years - 70 Years | Centre Francois Baclesse | |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | NCT02154529 | HER-2 Positive ... Metastatic Mali... | Tesevatinib Trastuzumab | 18 Years - | Kadmon Corporation, LLC | |
| Palbociclib In Progressive Brain Metastases | NCT02896335 | Metastatic Mali... | Palbociclib | 18 Years - | Massachusetts General Hospital | |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors | NCT02038218 | Primary Brain T... Metastatic Mali... | 4-Demethyl-4-ch... | 18 Years - | DEKK-TEC, Inc. | |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | NCT02154529 | HER-2 Positive ... Metastatic Mali... | Tesevatinib Trastuzumab | 18 Years - | Kadmon Corporation, LLC | |
| Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | NCT01332929 | Metastatic Mali... | Bevacizumab | 18 Years - 70 Years | Centre Francois Baclesse | |
| Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis | NCT01705548 | Metastatic Mali... Unspecified Adu... | Hypofractionate... | 18 Years - | Emory University | |
| Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases | NCT04801342 | Metastatic Mali... | Conformal Whole... Conformal Whole... Memantine Hydro... | 20 Years - | National Taiwan University Hospital | |
| Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases | NCT02393131 | Metastatic Mali... | Hippocampal avo... Conformal WBRT | 20 Years - | National Taiwan University Hospital | |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors | NCT02038218 | Primary Brain T... Metastatic Mali... | 4-Demethyl-4-ch... | 18 Years - | DEKK-TEC, Inc. | |
| Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases | NCT04801342 | Metastatic Mali... | Conformal Whole... Conformal Whole... Memantine Hydro... | 20 Years - | National Taiwan University Hospital | |
| Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases | NCT00928226 | Brain Cancer Neoplasm Metast... Cancer of Brain... Metastatic Mali... | Fractionated St... Surgical resect... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
